On September 3-4, 2020, the China Drug Frontier Technology—Special Formulations Summit, hosted by the Transdermal Drug Delivery Committee of the World Federation of Chinese Medicine Societies and guided by the Shandong Provincial Institute for Food and Drug Control, was successfully held in Jinan, the Spring City.

How can biopharmaceutical companies in the Greater Bay Area seize these opportunities and overcome challenges to achieve greater growth? On the afternoon of June 29, the Guangdong Association for Biomedical Innovation Technology partnered with Guangzhou DiQi Pharmaceuticals Co., Ltd. to host a salon event on Guangzhou Bio Island. The event centered on the theme: “How Pharmaceutical Companies in the Greater Bay Area Can Seize Opportunities and Pursue Collaborative Development in the Post-Pandemic Era.”

On March 25, 2020, the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod), a new Class 1 drug, for the treatment of relapsing multiple sclerosis. Developed by Celgene, Zeposia (ozanimod) is the first new drug approved by the U.S. FDA since Bristol-Myers Squibb completed its acquisition of Celgene. Zeposia is available as a standard capsule in strengths of 0.23 mg, 0.46 mg, and 0.92 mg. The dosing regimen involves taking 0.23 mg orally on days 1–4, 0.46 mg orally on days 5–7, and 0.92 mg orally daily starting on day 8. Clinical indications include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ozanimod exhibits high oral bioavailability, with a Tmax of approximately 6–8 hours post-oral administration and a mean elimination half-life of 21 hours.